Perugi Giulio, Frare Franco, Toni Cristina
Department of Psychiatry, University of Pisa, Pisa, Italy.
CNS Drugs. 2007;21(9):741-64. doi: 10.2165/00023210-200721090-00004.
Agoraphobia with panic disorder is a phobic-anxious syndrome where patients avoid situations or places in which they fear being embarrassed, or being unable to escape or get help if a panic attack occurs. During the last half-century, agoraphobia has been thought of as being closely linked to the recurring panic attack syndrome, so much so that in most cases it appears to be the typical development or complication of panic disorder. Despite the high prevalence of agoraphobia with panic disorder in patients in primary-care settings, the condition is frequently under-recognised and under-treated by medical providers. Antidepressants have been demonstrated to be effective in preventing panic attacks, and in improving anticipatory anxiety and avoidance behaviour. These drugs are also effective in the treatment of the frequently coexisting depressive symptomatology. Among antidepressant agents, SSRIs are generally well tolerated and effective for both anxious and depressive symptomatology, and these compounds should be considered the first choice for short-, medium- and long-term pharmacological treatment of agoraphobia with panic disorder. The few comparative studies conducted to date with various SSRIs reported no significant differences in terms of efficacy; however, the SSRIs that are less liable to produce withdrawal symptoms after abrupt discontinuation should be considered the treatments of first choice for long-term prophylaxis. Venlafaxine is not sufficiently studied in the long-term treatment of panic disorder, while TCAs may be considered as a second choice of treatment when patients do not seem to respond to or tolerate SSRIs. High-potency benzodiazepines have been shown to display a rapid onset of anti-anxiety effect, having beneficial effects during the first few days of treatment, and are therefore useful options for short-term treatment; however, these drugs are not first-choice medications in the medium and long term because of the frequent development of tolerance and dependence phenomena. Cognitive-behavioural therapy is the best studied non-pharmacological approach and can be applied to many patients, depending on its availability.
伴有惊恐障碍的场所恐惧症是一种恐惧焦虑综合征,患者会回避那些他们担心会尴尬,或者在惊恐发作时无法逃脱或获得帮助的情境或场所。在过去的半个世纪里,场所恐惧症一直被认为与反复出现的惊恐发作综合征密切相关,以至于在大多数情况下,它似乎是惊恐障碍的典型发展或并发症。尽管在初级保健机构的患者中,伴有惊恐障碍的场所恐惧症患病率很高,但这种疾病经常未被医疗服务提供者充分认识和治疗。抗抑郁药已被证明对预防惊恐发作、改善预期焦虑和回避行为有效。这些药物对经常同时存在的抑郁症状也有效。在抗抑郁药中,选择性5-羟色胺再摄取抑制剂(SSRI)通常耐受性良好,对焦虑和抑郁症状均有效,这些药物应被视为伴有惊恐障碍的场所恐惧症短期、中期和长期药物治疗的首选。迄今为止,对各种SSRI进行的少数比较研究报告称,在疗效方面没有显著差异;然而,突然停药后不易产生戒断症状的SSRI应被视为长期预防的首选治疗方法。文拉法辛在惊恐障碍的长期治疗方面研究不足,而当患者似乎对SSRI无反应或不耐受时,三环类抗抑郁药(TCA)可被视为第二选择的治疗方法。高效苯二氮䓬类药物已被证明具有快速起效的抗焦虑作用,在治疗的头几天有有益效果,因此是短期治疗的有用选择;然而,由于频繁出现耐受性和依赖性现象,这些药物在中长期不是首选药物。认知行为疗法是研究得最好的非药物治疗方法,根据其可及性可应用于许多患者。